Login / Signup

An expanded access protocol of RT001 in amyotrophic lateral sclerosis-Initial experience with a lipid peroxidation inhibitor.

Megan YertonAllison WinterAnthony KostovCassandra LiebermanDario GelevskiHarli WeberMichael DoyleGeli KaneNeil ParikhKatherine M BurkeMargot RohrerTaylor StirratMargaret BrunoAlison HochmanSarah LuppinoJennifer ScaliaDebra SkonieckiDerek D'AgostinoErvin SinaniHong YuAlexander V ShermanSuma BabuJames D BerryMark G MideiPeter G MilnerMerit E CudkowiczSabrina Paganoni
Published in: Muscle & nerve (2022)
RT001 was administered safely to a small group of people living with ALS in the context of an EA protocol. Currently, there is an ongoing randomized, double-blind, controlled study of RT001 in ALS.
Keyphrases
  • double blind
  • placebo controlled
  • randomized controlled trial
  • phase iii
  • amyotrophic lateral sclerosis
  • clinical trial
  • phase ii
  • study protocol